IP Library Granted Patent US 8,840,865
Granted Patent B2
US 8,840,865 · App. 14/041,643 · Granted Sep 23, 2014

Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,840,865
App. No.
14/041,643
Granted
Sep 23, 2014
Kind
B2
Abstract

Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecu le, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.

Claims (50)

1. A compound represented by:

a pharmaceutically acceptable salt thereof;

f is an integer from 0 to 12; and

g is an integer from 0 to 12.

2. The compound of claim 1 , wherein f is 2 to 10.

3. The compound of claim 1 , wherein f is 4.

4. The compound of claim 1 , wherein g is 2 to 10.

5. The compound of claim 1 , wherein g is 4.

6. The compound of claim 1 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

7. The compound of claim 6 , wherein f is 4.

8. The compound of claim 1 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

9. The compound of claim 8 , wherein g is 4.

10. The compound of claim 1 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

11. The compound of claim 10 , wherein g is 4.

12. The compound of claim 1 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

13. The compound of claim 12 , wherein f is 4.

14. A method of preparing a peptide conjugate incorporating a compound, the method comprising synthesizing the peptide conjugate using solid-phase peptide-synthesis techniques;

wherein:

the compound is:

a pharmaceutically acceptable salt thereof;

f is an integer from 0 to 12; and

g is an integer from 0 to 12.

15. The method of claim 14 , wherein f is 2 to 10.

16. The method of claim 14 , wherein f is 4.

17. The method of claim 14 , wherein g is 2 to 10.

18. The method of claim 14 , wherein g is 4.

19. The method of claim 14 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

20. The method of claim 19 , wherein f is 4.

21. The method of claim 14 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

22. The method of claim 21 , wherein g is 4.

23. The method of claim 14 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

24. The method of claim 23 , wherein g is 4.

25. The method of claim 14 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

26. The method of claim 25 , wherein f is 4.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC
Reel/Frame 062047/0915 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Aug 19, 2020
From: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY LLC
To: WELLS FARGO BANK, N.A.
Reel/Frame 053538/0666 →